Abstract: The present invention relates to recombinant albumins fused with poly-cysteine peptide and methods for preparing the same, more precisely recombinant albumins in which cysteines that can be used for drug binding are amplified at N-terminal and C-terminal of the albumin and methods for preparing the same. The recombinant albumin of the present invention demonstrates improved albumin-drug conjugation efficiency when it is used for drug delivery system, indicating that it can effectively deliver a large amount of drug to a target tissue. At the same time, the recombinant albumin of the present invention can be used as an excellent drug deliverer with reduced side effects, compared with the conventional albumin carriers, by regulating the amount of drug conjugated to each unit of albumin by regulating the number of cysteine fused thereto.
Type:
Grant
Filed:
June 2, 2010
Date of Patent:
September 24, 2013
Assignee:
Korea Institute of Science and Technology
Inventors:
Hyung Jun Ahn, Ick Chan Kwon, Kuiwon Choi, Kwangmyeng Kim, Inchan Youn, Sehoon Kim
Abstract: The present invention relates to a peptide of general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AA)p-R2, derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.
Type:
Grant
Filed:
December 23, 2009
Date of Patent:
September 10, 2013
Assignee:
ISP Investments Inc.
Inventors:
Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
Abstract: A method of preparing a water-soluble and biodegradable antimicrobial agent is provided. The method includes treating a polypeptide compound with sodium hypochlorite for at least 1 min, such that the polypeptide compound has at least one N-halamine group and has good antimicrobial effect. By using the method of the present invention, a chemical synthesis process is not required and an organic solvent is not required either, and thus, an antimicrobial agent having high water solubility, biodegradability, non-toxicity, good sterilization effect, and regeneration can be prepared with reduced harms to the environment.
Abstract: Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments The invention relates to heterocyclically substituted methoxyphenyl derivatives with an oxo group, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R10, X, n, B1, B2, B3 and B4 are each defined as specified, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.
Type:
Grant
Filed:
June 7, 2011
Date of Patent:
September 10, 2013
Assignee:
Sanofi
Inventors:
Stefanie Keil, Elisabeth Defossa, Viktoria Dietrich, Siegfried Stengelin, Andreas Herling, Guido Haschke, Thomas Klabunde
Abstract: Disclosed is a method of improving the conditioned reflex habit, the muscle tonus, or the motion coordination of a patient after suffering trauma to the brain cortex that involves administering to the patient an effective amount of a composition containing peptide glutamyl-aspartyl-arginine of the formula H-Glu-Asp-Arg-OH as its active base.
Type:
Grant
Filed:
August 15, 2012
Date of Patent:
September 3, 2013
Assignee:
Obschestvo S Ogranichennoi Otvetstvennostyu “Sia Peptides”
Inventors:
Vladimir Khatskelevich Khavinson, Evgeny Iosifovich Grigoriev, Vladimir Victorovich Malinin, Galina Anatolievna Ryzhak
Abstract: The present invention relates to nanopeptides isolated from mammalian colostrum with vaccine like antiviral and immunodulator activity via building body's own immune system and attachment inhibition on the cell surface receptors.
Abstract: The present invention provides a CCN3 peptide for treating a subject in need thereof having an amino acid sequence identified as CCNp37, CCNp38 (human), CCNp38 (mouse), a cysteine-substituted CCNp37, cysteine-substituted CCNp38 (human) or a cysteine-substituted CCNp38 (mouse).
Type:
Grant
Filed:
April 4, 2011
Date of Patent:
August 27, 2013
Assignee:
Rosalind Franklin University of Medicine and Science
Abstract: The present invention provides for novel peptides derived from human milk. In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk substitutions, infant formula., mother's milk, parenteral nutrition solutions, cell/tissue/organ storage and perfusion solutions and pharmaceutical formulations.
Type:
Grant
Filed:
June 1, 2010
Date of Patent:
August 27, 2013
Inventors:
Kenneth James Friel, Apollinaire Tsopmo
Abstract: The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. Another aspect of the invention provides for the use of the disclosed compounds for treating Type II diabetes, insulin resistance, glucose intolerance, hyperglycemia, hypoglycemia, hyperinsulinemia, obesity, hyperlipidemia, or hyperlipoproteinemia.
Type:
Grant
Filed:
March 1, 2010
Date of Patent:
August 20, 2013
Assignee:
Trustees of Tufts College
Inventors:
William W. Bachovchin, Hung-sen Lai, Wengen Wu
Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
Abstract: C-terminal endostatin polypeptides are disclosed herein. In some embodiments, these polypeptides include or consist of (1) at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; (2) at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions, (3) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; or (4) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions; wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4.
Type:
Grant
Filed:
October 22, 2010
Date of Patent:
August 13, 2013
Assignee:
University of Pittsburgh—Of the Commonwealth Systems of Higher Education
Inventors:
Carol A. Feghali-Bostwick, Yukie Yamaguchi
Abstract: The invention refers to a synthetic peptide comprising an amino acid sequence of seven residues in length, preferably flanked by 2 cysteine residues at both ends, which is capable of specifically recognizing human CD154 and blocking CD40:CD154 interaction, thereby inhibiting the biological effects depending on such interaction. The peptide of the invention, which is preferably in a cyclic form, is suitable for use for diagnostic and therapeutic applications, especially for the diagnosis and therapy of tumor, inflammatory diseases and transplant rejection.
Type:
Grant
Filed:
November 27, 2008
Date of Patent:
August 13, 2013
Assignee:
Fresenius Medical Care Deutschland G.m.b.H.
Abstract: The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; R1 is selected from the group consisting of —CH2NH2, and R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl; R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and R4 is selected from the group consisting of —OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(?O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H, a simple (C1-C3) alkyl or a simple (C1-C3) acyl.
Type:
Grant
Filed:
December 21, 2011
Date of Patent:
July 30, 2013
Assignee:
The Medicines Company (Leipzig) GmbH
Inventors:
Peter Herold, Stjepan Jelakovic, Mohammed Daghish, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz, Friedrich-Alexander Ludwig, Adel Rafai Far, Ting Kang
Abstract: The embodiments provide Compound KC-7, N-1-[(S)-2-(oxycodone-6-enol-carbonyl-methyl-amino)-2-carbonyl-sarcosine-ethyl amine]-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the \compositions comprise a prodrug, Compound KC-7, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
Type:
Grant
Filed:
February 28, 2011
Date of Patent:
July 30, 2013
Assignee:
Tranzyme Pharma Inc.
Inventors:
Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
Abstract: Disclosed are tri-nuclear metal complexes and salts thereof, such as tri-nuclear osmium or ruthenium complexes or salts thereof, suitable for use as electrochemical labels. Also disclosed are oligonucleotide probes with an attached electrochemical label, methods of nucleic acid amplification, methods of sequencing, and kits for nucleic acid amplification and sequencing having oligonucleotide probes including an electrochemical label. The electrochemical labels are synthesized from siderophores.
Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.
Abstract: Disclosed herein are multi-component formulations for enzymatically producing aqueous solutions of peroxycarboxylic acids suitable for use in, e.g., disinfectant and/or bleaching applications. The multi-component peroxycarboxylic acid formulations comprise at least one carbohydrate esterase family 7 enzyme having perhydrolytic activity.
Type:
Grant
Filed:
September 11, 2012
Date of Patent:
July 16, 2013
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Robert Dicosimo, Arie Ben-Bassat, William R. Cahill, David George Dipietro, Eugenia Costa Hann, Mark S. Payne, Richard Alan Reynolds, Raymond Richard Zolandz
Abstract: This invention involves compositions and method of using of therapeutic agents for pain relief for the treatment and prevention of disorders associated with endothelial dysfunction, the cause of inflammation, atherosclerosis, cardiovascular disease, diabetes, hypertension, asthma and stroke in mammals comprising anti-inflammatory agents, epinephrine, insulin, anti-viral agents and dietary supplements.